A Randomized, Double-Blind, Placebo-Controlled, Two-Part Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Humans
Latest Information Update: 27 May 2024
At a glance
- Drugs REGN 5381 (Primary)
- Indications Hypertension
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
- 08 Apr 2024 Results exploring the pharmacodynamic response in 2 hypertensive animal models and safety and tolerability presented at the 73rd Annual Scientific Session of the American College of Cardiology
- 13 Nov 2023 Results (n=48) of safety and pharmacodynamic (PD) outcomes in normotensive humans , presented at the American Heart Association Scientific Sessions 2023
- 19 Dec 2022 Status changed from active, no longer recruiting to completed.